• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.

作者信息

Menzies Alexander M, Pires da Silva Ines, Trojaniello Claudia, Vieu Elisabeth, Amaria Rodabe N, Zimmer Lisa, Lo Serigne N, Burton Elizabeth M, Tawbi Hussein A, Schadendorf Dirk, Grob Jean J, Ascierto Paolo A, Long Georgina V

机构信息

Melanoma Institute Australia, Sydney, NSW, Australia.

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.

出版信息

N Engl J Med. 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768.

DOI:10.1056/NEJMc2119768
PMID:35476655
Abstract
摘要

相似文献

1
CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.瑞帕利单抗和纳武利尤单抗治疗后的CTLA-4阻断抗性
N Engl J Med. 2022 Apr 28;386(17):1668-1669. doi: 10.1056/NEJMc2119768.
2
A decade of immune-checkpoint inhibitors in cancer therapy.免疫检查点抑制剂在癌症治疗中的十年。
Nat Commun. 2020 Jul 30;11(1):3801. doi: 10.1038/s41467-020-17670-y.
3
Three more immune checkpoint inhibitors for advanced bladder cancer.又有三种免疫检查点抑制剂用于晚期膀胱癌。
Med Lett Drugs Ther. 2017 Dec 4;59(1535):e202-e203.
4
Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.免疫检查点抑制剂相关垂体炎——世界卫生组织药物不良反应数据库报告分析
Eur J Cancer. 2019 May;113:10-13. doi: 10.1016/j.ejca.2019.03.002. Epub 2019 Apr 4.
5
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.免疫检查点阻断治疗转移性黑色素瘤中 CTLA-4 和 PD-1 抗体的副作用管理 - 最新进展。
J Dtsch Dermatol Ges. 2020 Jun;18(6):582-609. doi: 10.1111/ddg.14128. Epub 2020 Jun 3.
6
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.靶向多个受体以提高检查点阻断疗效。
Int J Mol Sci. 2019 Jan 4;20(1):158. doi: 10.3390/ijms20010158.
7
Checkpoint blockade after kidney transplantation.肾移植后的检查点阻断
Eur J Cancer. 2018 Jun;96:111-114. doi: 10.1016/j.ejca.2018.03.019. Epub 2018 Apr 26.
8
[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].[新的美国医学杂志文章：纳武单抗用于一线化疗后的晚期食管鳞状细胞癌]
Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.
9
Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.在错配修复缺陷转移性结直肠癌患者中，PD-1 阻断进展期间和随后 CTLA-4 解救时的循环肿瘤 DNA（ctDNA）连续分析。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003312.
10
Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.系统评价和荟萃分析抗 PD-1 进展的晚期黑色素瘤患者中免疫检查点抑制剂的疗效和安全性：系统评价和荟萃分析。
Clin Transl Oncol. 2021 Sep;23(9):1885-1904. doi: 10.1007/s12094-021-02598-6. Epub 2021 Apr 20.

引用本文的文献

1
Engineered exosomes: a promising design platform for overcoming cancer therapy resistance.工程化外泌体：一种克服癌症治疗耐药性的有前景的设计平台。
Front Cell Dev Biol. 2025 Aug 6;13:1608480. doi: 10.3389/fcell.2025.1608480. eCollection 2025.
2
The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma.治疗抗程序性死亡蛋白1（PD-1）耐药的晚期黑色素瘤的挑战
Am J Clin Dermatol. 2025 Jul 17. doi: 10.1007/s40257-025-00969-1.
3
The progress and prospects of targeting the adenosine pathway in cancer immunotherapy.癌症免疫治疗中靶向腺苷途径的进展与前景
Biomark Res. 2025 May 19;13(1):75. doi: 10.1186/s40364-025-00784-0.
4
Overcoming Resistance Mechanisms to Melanoma Immunotherapy.克服黑色素瘤免疫疗法的耐药机制
Am J Clin Dermatol. 2025 Jan;26(1):77-96. doi: 10.1007/s40257-024-00907-7. Epub 2024 Dec 5.
5
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.冷冻消融联合转移性黑色素瘤进展后免疫检查点抑制：一项 II 期试验。
Nat Commun. 2024 Aug 27;15(1):7357. doi: 10.1038/s41467-024-51722-x.
6
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.一线纳武利尤单抗联合雷莫芦单抗对比纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤：基于 RELATIVITY-047 和 CheckMate 067 试验数据的间接治疗比较。
J Clin Oncol. 2024 Nov 20;42(33):3926-3934. doi: 10.1200/JCO.24.01125. Epub 2024 Aug 13.
7
Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.淋巴细胞激活基因 3 和程序性细胞死亡蛋白 1 抗体在癌症治疗中的研究进展：综述。
Biomol Biomed. 2024 Apr 6;24(4):764-774. doi: 10.17305/bb.2024.10339.
8
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.黑色素瘤中LAG-3检查点阻断疗法的引入：超越PD-1和CTLA-4抑制的免疫治疗格局
Ther Adv Med Oncol. 2023 Jul 17;15:17588359231186027. doi: 10.1177/17588359231186027. eCollection 2023.
9
Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma.乐伐替尼联合抗程序性死亡蛋白1（PD-1）作为转移性黑色素瘤晚期治疗方案的真实世界证据。
Front Oncol. 2023 May 18;13:1180988. doi: 10.3389/fonc.2023.1180988. eCollection 2023.
10
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.在免疫检查点抑制剂和靶向治疗进展后，晚期黑色素瘤患者单次自体肿瘤浸润淋巴细胞（TIL）细胞治疗 lifileucel 的疗效和安全性：C-144-01 研究连续队列的汇总分析。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005755.